SABCS® Daily Highlights for Friday, December 8


Estimated Read Time:

4 minutes

By Kate Lathrop, MD
SABCS® Program Director,
SABCS® Executive and Program Planning Committees

Kate Lathrop, MD
Kate Lathrop, MD

Welcome to the final full day of the 2023 San Antonio Breast Cancer Symposium®! It has been an educational, enlightening, and inspiring week of captivating breast cancer science, research, and patient advocacy. Thank you for being here and participating in this Symposium, whether it’s your first experience or you’ve attended for years.

There’s still plenty of science to cover today; check the program listings to see the most up-to-date schedule. The final Concurrent Poster Spotlight Session begins at 7:00 a.m., and 25 posters will be presented under three topics:

  • PS16: Enhancing Immunotherapy for Triple Negative Breast Cancer: Novel Therapies and Biomarkers will be held in Stars at Night Ballroom 3-4, with moderator Hope S. Rugo, MD, FASCO, University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
  • PS17: Biomarkers of Response and/or Resistance to Endocrine Based Therapies: Implications for Treatment Approaches will be held in Hemisfair Ballroom 1–2 with moderator Komal Jhaveri, MD, FACP, Memorial Sloan Kettering Cancer Center.
  • PS18: Disparate Care Calls for Desperate Measures:  Understanding Gaps in Quality of Care and Opportunities to Improve It will be held in Stars at Night Ballroom 1–2 with moderator Debra Patt, MD, PhD, MBA, Texas Oncology.

General Session 3, which begins at 8:15 a.m. CT in Hall 1, keeps the momentum of research going with 11 abstract presentations. Mothaffar F. Rimawi, MD, Baylor College of Medicine, and Mylin A. Torres, MD, Winship Cancer Institute of Emory University, will co-moderate the discussions, including these hot topics: 

  • GS03-01–Magnetic resonance imaging and a 12-gene expression assay to optimize local therapy for ductal carcinoma in situ: 5-year clinical outcomes of E4112

Seema Khan, MD, Northwestern University, will present.

  • GS03-02–Mammographic surveillance in early breast cancer patients aged 50 years or over: Results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography

Janet A. Dunn, PhD, University of Warwick, United Kingdom, will present.

  • GS03-12 – Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis

Sibylle Loibl, MD, PhD German Breast Group, Neu-Isenburg, Germany, will present.

  • GS03-13 – Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis”.

Komal Jhaveri, MD, FACP, Clinical Director, Early Drug Development Service at Memorial Sloan Kettering Cancer Center, will present.

At 11:15 a.m. CT, Hall 1 will transition for the second Plenary Lecture at the 2023 SABCS®. Recent Advances in Triple-Negative Breast Cancer will be presented by lecturer Melinda L. Telli, MD, Stanford University School of Medicine, who will look at why the prognosis is shifting for triple-negative breast cancer patients.

Don’t miss the AACR Outstanding Investigator Award for Breast Cancer Research, supported by Breast Cancer Research Foundation. Alana L. Welm, PhD, Huntsman Cancer Institute, is the recipient of the award, which was established to honor an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer. Dr. Welm’s lecture will be at 1:00 p.m. CT in Stars at Night Ballroom 1–2.

SABCS® will wrap up this year’s meeting with Year in Review and View from the Trenches, two of the most popular sessions of the Symposium. Year in Review, which will be at 2:40 p.m. in Stars at Night Ballroom 1–2, will feature a panel of experts giving a snapshot of four important developments in breast cancer this year. View from the Trenches, set for 5:00 p.m. CT in Hall 1, will review the practice-changing data from this year’s Symposium, giving you the tools and information you need to take back to your clinic or institution on Monday. Enjoy cocktail hour with a panel of breast cancer experts taking your questions and debating the clinical impact of the trials presented at the 2023 SABCS®.   

Enjoy this last full day of education! If you are participating in Saturday’s half-day Career Development Forum, I look forward to seeing you there.

Check for more meeting highlights, session recaps, and all the news from the 2023 SABCS®.